샘플 요청 목록

 카트 문의
시장보고서
상품코드
1783997

세계의 전이성 폐선암 치료 시장

Metastatic Lung Adenocarcinoma Treatment
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 286 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

전이성 폐선암 치료 세계 시장은 2030년까지 86억 달러에 달할 전망

2024년에 48억 달러로 추정되는 전이성 폐선암 치료 세계 시장은 2024-2030년 분석 기간 동안 CAGR 10.5%로 성장하여 2030년에는 86억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 화학요법은 CAGR 8.3%를 기록하며 분석 기간 종료시에는 26억 달러에 달할 것으로 예측됩니다. 표적요법 분야의 성장률은 분석 기간 동안 CAGR 12.5%로 추정됩니다.

미국 시장은 13억 달러로 추정, 중국은 CAGR 13.9%로 성장 예측

미국의 전이성 폐선암 치료 시장은 2024년에 13억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 17억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 13.9%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 7.7%와 9.1%로 예측됩니다. 유럽에서는 독일이 CAGR 약 8.2%로 성장할 것으로 예측됩니다.

세계의 전이성 폐선암 치료 시장 - 주요 동향과 촉진요인 정리

전이성 폐선암이란 무엇이며, 어떻게 치료하는가?

전이성 폐선암은 비소세포폐암(NSCLC)의 말기형으로 폐에서 발생한 암이 뇌, 뼈, 간, 부신 등 원격 장기로 전이되는 질환입니다. 비소세포폐암의 가장 흔한 아형이며, 전체 폐암의 40-50% 정도를 차지합니다. 이 병기는 특히 침습성이 강해 수술이나 방사선 치료와 같은 국소 치료보다는 전신요법을 포함한 다제 병용요법이 필요한 경우가 많습니다. 전이성 환자의 주요 치료 목표는 질병의 진행을 늦추고, 생존 기간을 연장하고, 환자의 삶의 질을 개선하거나 유지하는 것입니다.

치료 전략은 고도로 개별화되어 있으며, 종양의 분자 및 유전자 프로파일링에 의해 유도되는 경우가 많습니다. 표적 치료제, 면역관문억제제, 첨단 화학요법이 현대 치료 계획의 핵심을 이루고 있습니다. EGFR, ALK, ROS1, BRAF와 같은 특정 돌연변이를 표적으로 하는 약물은 더 높은 반응률과 무진행생존기간 연장을 가져와 일부 환자의 결과를 크게 변화시켰습니다. 면역요법, 특히 PD-1 억제제와 PD-L1 억제제는 단독으로 또는 화학요법과 병용하여 특히 실용적인 돌연변이가 없는 환자들을 위한 최전선 치료법으로 부상하고 있습니다. 종양 생물학에 대한 이해가 깊어짐에 따라, 치료 프로토콜은 환자별 특성에 맞게 지속적으로 진화하고 있습니다.

기술적, 임상적 발전과 함께 시장은 어떻게 진화하고 있는가?

전이성 폐선암의 치료 상황은 정밀 종양학, 동반진단, 약물 개발의 획기적인 발전에 힘입어 지난 10년간 패러다임의 전환을 이루었습니다. 액체 생검과 차세대 염기서열 분석(NGS) 기술의 출현으로 종양 전문의는 실용적인 유전자 변화를 비침습적으로 검출할 수 있게 되었고, 적시에 정확한 치료법을 선택할 수 있게 되었습니다. 이러한 기술 혁신은 치료까지의 시간을 단축하고, 빠르게 진행되는 전이성 질환을 관리하는 데 있어 중요한 요소인 치료 실패의 위험을 최소화하고 있습니다.

이와 함께 의약품 파이프라인도 빠르게 확장되고 있으며, 광범위한 분자 돌연변이를 표적으로 하는 수많은 신약이 현재 후기 임상시험 단계에 있거나 최근 승인되었습니다. KRAS G12C 억제제, MET 억제제, RET 융합 표적 치료제 등의 약물은 맞춤치료에 새로운 국면을 가져오고 있습니다. 또한, 면역관문억제제와 항혈관신생제 및 항암화학요법과의 병용 전략은 임상시험에서 전체 생존기간의 개선을 보여줌으로써 표준 치료의 알고리즘을 재구성하고 있습니다. 시장은 또한 종양 미세환경 조절제 및 T세포 인게이저에 대한 관심이 증가하고 있으며, 이는 치료가 돌연변이 특이적일 뿐만 아니라 면역학적 반응과 깊이 통합된 미래가 될 것임을 시사합니다.

전이성 폐선암 치료 시장의 성장은 몇 가지 요인에 의해 주도됩니다.

전이성 폐선암 치료 시장의 개척은 몇 가지 요인에 의해 촉진되고 있습니다. 주요 요인으로는 전 세계 폐암 발병률 증가, 특히 고령화 사회와 개발도상국 흡연자의 폐암 발병률 증가를 꼽을 수 있습니다. 인지도 향상, 스크리닝 프로그램 개선, 진단 인프라의 개선으로 전이가 보다 정확하고 조기에 발견되어 고급 전신 치료의 대상이 되는 환자층이 확대되고 있습니다. 또한, 폐암 환자의 비율이 증가하는 가운데 실용적인 유전자 변이가 확인됨에 따라 표적 치료가 보다 광범위하게 적용되어 정밀의료의 혁신과 보급을 촉진하고 있습니다.

진단 도구의 기술적 진보, 특히 액체 생검과 종합적인 유전체 프로파일링의 급속한 도입은 보다 개인화된 치료 요법을 촉진하고 환자 결과를 개선하고 있습니다. 또한, 미국, 유럽, 중국 등 주요 시장에서는 규제 프레임워크가 정비되고 승인이 가속화되고 있어 혁신적인 암 치료제의 시장 진입이 가속화되고 있습니다. 바이오제약 기업의 활발한 연구개발 투자, 학계와 산업계와의 협력관계 강화, 신흥국의 헬스케어 적용범위 확대도 시장 확대에 기여하고 있습니다. 이러한 요인들이 결합되어 전 세계 전이성 폐선암 분야에서 보다 효과적이고 독성이 낮으며 환자 중심의 치료 솔루션에 대한 수요가 증가하고 있습니다.

부문

치료(화학요법, 표적요법, 면역요법, 방사선 치료, 기타), 최종사용자(병원, 전문 클리닉, 기타)

조사 대상 기업 사례

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca
  • Bayer AG
  • BioNTech SE
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • GSK plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals
  • Roche
  • Sanofi
  • Summit Therapeutics
  • Takeda Pharmaceutical Company

AI 통합

우리는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 일반적인 LLM 및 업계별 SLM 쿼리를 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

ksm 25.08.11

Global Metastatic Lung Adenocarcinoma Treatment Market to Reach US$8.6 Billion by 2030

The global market for Metastatic Lung Adenocarcinoma Treatment estimated at US$4.8 Billion in the year 2024, is expected to reach US$8.6 Billion by 2030, growing at a CAGR of 10.5% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 8.3% CAGR and reach US$2.6 Billion by the end of the analysis period. Growth in the Targeted Therapy segment is estimated at 12.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 13.9% CAGR

The Metastatic Lung Adenocarcinoma Treatment market in the U.S. is estimated at US$1.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2030 trailing a CAGR of 13.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.7% and 9.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.2% CAGR.

Global Metastatic Lung Adenocarcinoma Treatment Market - Key Trends & Drivers Summarized

What is Metastatic Lung Adenocarcinoma and How is It Treated?

Metastatic lung adenocarcinoma is a late-stage form of non-small cell lung cancer (NSCLC), where the cancer originating in the lungs spreads (metastasizes) to distant organs such as the brain, bones, liver, or adrenal glands. It is the most common subtype of NSCLC, accounting for nearly 40-50% of all lung cancer cases. The disease is particularly aggressive at this stage and often requires a multimodal treatment approach that includes systemic therapies rather than localized interventions such as surgery or radiotherapy. The primary treatment goals for metastatic cases are to slow disease progression, prolong survival, and improve or maintain the patient’s quality of life.

Treatment strategies are highly individualized and increasingly guided by molecular and genetic profiling of tumors. Targeted therapies, immune checkpoint inhibitors, and advanced chemotherapy regimens form the core of contemporary treatment plans. Drugs that target specific mutations such as EGFR, ALK, ROS1, and BRAF have significantly changed outcomes for subsets of patients, offering higher response rates and extended progression-free survival. Immunotherapies-particularly PD-1 and PD-L1 inhibitors-have also emerged as frontline treatments, either alone or in combination with chemotherapy, especially for patients without actionable mutations. As understanding of tumor biology deepens, treatment protocols are continuously evolving to align with patient-specific characteristics.

How is the Market Evolving with Technological and Clinical Advancements?

The treatment landscape for metastatic lung adenocarcinoma has undergone a paradigm shift over the past decade, driven by breakthroughs in precision oncology, companion diagnostics, and drug development. The emergence of liquid biopsies and next-generation sequencing (NGS) technologies has enabled oncologists to detect actionable genetic alterations non-invasively, allowing for timely and accurate therapy selection. These innovations are reducing the time to treatment and minimizing the risk of ineffective therapies, a critical factor in managing fast-progressing metastatic disease.

In parallel, the pharmaceutical pipeline has expanded rapidly, with numerous novel agents targeting a wider range of molecular mutations currently in late-stage clinical trials or recently approved. Agents like KRAS G12C inhibitors, MET inhibitors, and RET fusion-targeting drugs are adding new dimensions to personalized treatment. Furthermore, combination strategies-such as pairing immune checkpoint inhibitors with anti-angiogenic agents or chemotherapy-are demonstrating improved overall survival in clinical trials, reshaping standard-of-care algorithms. The market is also seeing increasing interest in tumor microenvironment modulation and T-cell engagers, pointing to a future where treatment is not only mutation-specific but also deeply integrated with immunologic responses.

The Growth in the Metastatic Lung Adenocarcinoma Treatment Market is Driven by Several Factors

The growth in the metastatic lung adenocarcinoma treatment market is driven by several factors, primarily the increasing global incidence of lung cancer, particularly in aging populations and among smokers in developing regions. Rising awareness, improved screening programs, and better diagnostic infrastructure are leading to more accurate and earlier detection of metastasis, thereby expanding the pool of patients eligible for advanced systemic therapies. Moreover, the identification of actionable genetic mutations in a growing proportion of lung cancer patients has enabled targeted therapy to be applied more broadly, driving both innovation and uptake of precision medicines.

Technological advancements in diagnostic tools, especially the rapid adoption of liquid biopsies and comprehensive genomic profiling, are facilitating more personalized treatment regimens and improving patient outcomes. In addition, favorable regulatory frameworks and accelerated approval pathways in key markets such as the U.S., Europe, and China are enabling faster market entry for innovative oncology drugs. Strong investment from biopharmaceutical companies in R&D, increasing collaboration between academia and industry, and expanding healthcare coverage in emerging economies are also contributing to market expansion. Collectively, these drivers are fueling the demand for more effective, less toxic, and patient-centric treatment solutions in the global metastatic lung adenocarcinoma space.

SCOPE OF STUDY:

The report analyzes the Metastatic Lung Adenocarcinoma Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment (Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Others); End-Use (Hospitals, Specialty Clinics, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca
  • Bayer AG
  • BioNTech SE
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • GSK plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals
  • Roche
  • Sanofi
  • Summit Therapeutics
  • Takeda Pharmaceutical Company

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Metastatic Lung Adenocarcinoma Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Non-Small Cell Lung Cancer Propels Demand for Advanced Therapeutics
    • Growing Emphasis on Precision Medicine Strengthens Business Case for Targeted Therapies
    • Increased Adoption of Next-Generation Sequencing (NGS) Drives Demand for Companion Diagnostics
    • Expanding Use of Biomarker-Based Stratification Expands Addressable Market Opportunity
    • Breakthroughs in Immunotherapy Accelerate Demand for Checkpoint Inhibitors
    • Expanding FDA Approvals for Targeted Therapies Spurs Growth in Treatment Options
    • Integration of AI in Drug Discovery Throws the Spotlight on Personalized Treatment Pathways
    • Rising Government and Private Sector Funding Supports Innovation in Oncology Research
    • Shift Toward Outpatient and Home-Based Cancer Care Models Drives Adoption of Oral Therapies
    • Increasing Use of Real-World Evidence (RWE) Strengthens Business Case for Therapy Reimbursement
    • Growing Demand for Minimal Side-Effect Profiles Propels Development of Novel Drug Delivery Systems
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Metastatic Lung Adenocarcinoma Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Metastatic Lung Adenocarcinoma Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Specialty Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Metastatic Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Metastatic Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Metastatic Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Metastatic Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Metastatic Lung Adenocarcinoma Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Metastatic Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Metastatic Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Metastatic Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Metastatic Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Metastatic Lung Adenocarcinoma Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Metastatic Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Metastatic Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Metastatic Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Metastatic Lung Adenocarcinoma Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Metastatic Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Metastatic Lung Adenocarcinoma Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Metastatic Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제